Merck KGaA (MKGAF)
(Delayed Data from OTC)
$175.03 USD
-6.97 (-3.83%)
Updated Aug 2, 2024 11:43 AM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MKGAF 175.03 -6.97(-3.83%)
Will MKGAF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MKGAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MKGAF
Here's What Could Help Merck KGaA (MKGAF) Maintain Its Recent Price Strength
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
MKGAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Merck KGaA (MKGAF) a Good Fit for 'Trend Investing'
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
Other News for MKGAF
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Mixed ...
Merck KGaA reports Q2 results
Merck KGaA falls after discontinuing head and neck cancer therapy
J.P. Morgan’s top picks within Defensives